Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.365 USD | -3.41% | -8.68% | +158.98% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+158.98% | 968M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024